Efficacy and Biomarker Development for Lung Cancer Treated With Immune Checkpoint Inhibitors

Recruiting now · Phase 3

Conditions studied: Lung Cancer

In brief

The purpose of the study is to find some biomarkers to predict the the adverse events of Immune Checkpoint Inhibitors monotherapy or plus platinum based chemotherapy in lung cancer.

Key facts

Study ID

NCT05055908

Run by

Hunan Province Tumor Hospital

People needed

12000

Starts

2021-10-01

Expected to finish

2027-09-14

Last updated by the study team

2024-08-02

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Understand the requirements and contents of the clinical trial, and provide a signed and dated informed consent form.
• Age ≥ 18 years.
• Histologically or cytologically confirmed lung cancer.
• Treated with Immune Checkpoint Inhibitors with or without chemotherapy.
• Predicted survival ≥ 12 weeks. 7. Adequate bone marrow hematopoiesis and organ function 8. Presence of measurable lesions according to RECIST 1.1.

You may not qualify if…

• Any conditions can not match for the Inclusion Criteria, includign do not have the data to perform Adverse Events evalutation.

Where it is running

• Hunan Cancer Hospital — Changsha, Hunan, China (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.